- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06681935
Defining Mechanisms of Surgical Site Infection After Oral Cancer Surgery
May 19, 2026 updated by: Joseph Zenga, Medical College of Wisconsin
The study design is an observational cohort study of patients undergoing standard of care oral cavity reconstruction.
An observational study is required to prospectively evaluate microbial and antibiotic mechanisms underlying surgical site infection after oral cavity reconstruction.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a single institution study at the Medical College of Wisconsin, given the feasibility of projected sample size accrual as well as the clinical and translational expertise at this location for investigating surgical site infection after oral cavity reconstruction.
Biospecimens collected will include oral, nasal, pharyngoesophageal, and skin microbial swabs, blood, and discard tissue samples obtained during standard of care oral cavity reconstruction surgery and an oral swab and nasal swab obtained post-operatively.
Study Type
Observational
Enrollment (Estimated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Medical College of Wisconsin Cancer Center Clinical Trials Office
- Phone Number: 8900 866-680-0505
- Email: cccto@mcw.edu
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Recruiting
- Froedtert & the Medical College of Wisconsin
-
Contact:
- Joseph Zenga, MD
- Phone Number: 414-955-0889
- Email: jyzenga@mcw.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
The projected sample size is 40 patients over 2 years.
The cohort will be oral cancer patients undergoing standard of care oral cavity reconstruction, which includes a planned surgical connection from the oral cavity to the neck soft tissues which is repaired through free or pedicled flap reconstruction.
Description
Inclusion Criteria:
- Provide signed and dated informed consent form. Subjects must have the capacity to consent for themselves.
- Willing to comply with all study procedures and be available for the duration of the study.
- Aged 21 years or older.
- Planned to undergo standard of care oral cavity reconstruction surgery with use of ampicillin/sulbactam as the prophylactic antibiotic agent administered.
- Oral cavity reconstruction surgery will be defined as any surgical procedure which includes a planned connection from the oral cavity to the neck soft tissues which is repaired with a free or regional tissue flap.
- History of oral or oropharyngeal cancer.
Exclusion Criteria:
- Allergy to ampicillin/sulbactam.
- Vulnerable populations including pregnant women and prisoners.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Subjects undergoing Oral Cavity Reconstruction
The cohort will be oral cancer patients undergoing standard of care oral cavity reconstruction.
|
This procedure includes a planned surgical connection from the oral cavity to the neck soft tissues which is repaired through free or pedicled flap reconstruction.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Source of bacteria leading to a surgical site infection
Time Frame: Up to 30 days
|
This is the number of subjects with surgical site infections with bacteria that originates from the oral cavity.
This will be determined by metagenomic mapping of bacterial strains causing surgical site infection back on to the metagenomic samples from their anatomic source (oral cavity, nasal cavity, pharyngoesophagus, donor site skin).
|
Up to 30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tissue antibiotic correlations
Time Frame: Up to 30 days
|
This is the number of subjects with tissue antibiotic concentrations that correlate with surgical site infection.
This will be accomplished by liquid chromatography/mass spectrometry (LC-MS) to assess for antibiotic concentration in tissue and blood during surgery.
|
Up to 30 days
|
|
Plasma antibiotic correlations
Time Frame: Up to 30 days
|
This is the number of subjects with plasma antibiotic concentrations that correlate with surgical site infection.
This will be accomplished by liquid chromatography/mass spectrometry (LC-MS) to assess for antibiotic concentration in tissue and blood during surgery.
|
Up to 30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Joseph Zenga, MD, Medical College of Wisconsin
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 29, 2025
Primary Completion (Estimated)
July 15, 2026
Study Completion (Estimated)
July 15, 2026
Study Registration Dates
First Submitted
November 7, 2024
First Submitted That Met QC Criteria
November 7, 2024
First Posted (Actual)
November 12, 2024
Study Record Updates
Last Update Posted (Actual)
May 22, 2026
Last Update Submitted That Met QC Criteria
May 19, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO00052346
- R21DE032844 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Cancer
-
Anil ChaturvediNational Taiwan University HospitalRecruitingOral Cancer | Oral Cancer Screening | Oral PrecancerTaiwan
-
Royal Surrey County Hospital NHS Foundation TrustCompleted
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustNot yet recruitingOral Cancer | Dysplasia | Mouth Cancer | Oral Lesions | Oral Pre-cancerUnited Kingdom
-
Combined Military Hospital, PakistanNational University of Medical Sciences, PakistanCompletedOral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity CancerPakistan
-
University of California, San FranciscoPerloff Family FoundationNot yet recruitingPediatric Cancer | Mucositis Oral | Oral Mucosa DiscomfortUnited States
-
University of WashingtonBlaze Bioscience Inc.TerminatedStage III Lip and Oral Cavity Cancer AJCC v8 | Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Stage IVA Lip and Oral Cavity Cancer AJCC v8United States
-
Centre Francois BaclesseTerminatedCancer | Cognitive Function | Compliance | Oral TherapiesFrance
-
University of Michigan Rogel Cancer CenterRecruitingStage III Lip and Oral Cavity Cancer AJCC v8 | Oral Cavity Squamous Cell Carcinoma | Stage I Lip and Oral Cavity Cancer AJCC v8 | Stage II Lip and Oral Cavity Cancer AJCC v8 | Stage IVA Lip and Oral Cavity Cancer AJCC v8United States
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Oral LeukoplakiaUnited States
-
Helsinki University Central HospitalKarolinska Institutet; University of HelsinkiCompletedPeriodontal Diseases | Biomarker in Early Diagnosis | Oropharyngeal Cancers | Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity CancerFinland
Clinical Trials on Oral Cavity Reconstruction
-
Institut Claudius RegaudRecruitingHead and Neck Cancer | Oropharynx Cancer | Oral Cavity CancerFrance
-
Centre Hospitalier Universitaire, AmiensRegional Council Picardie; Picardy - Regional health agency (ARS); Regional Observatory... and other collaboratorsRecruiting
-
Xinqiao Hospital of ChongqingCompletedNasopharyngeal CarcinomaChina
-
Stryker CraniomaxillofacialCompletedMandible; Deformity | Mandible Fracture | Mandibular Fractures | MANDIBLE | Orthognathic Surgical ProceduresUnited States
-
International Agency for Research on CancerRegional Cancer Centre TrivandrumCompleted
-
UNICANCERCompletedOropharynx Squamous Cell Carcinoma | Oral Cavity Squamous Cell CarcinomaFrance
-
Central Hospital, Nancy, FranceRecruitingInflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisFrance
-
Shanghai Ninth People's Hospital Affiliated to...Not yet recruitingOral Cancer | Tongue Squamous Cell Carcinoma | Free Flap | Virtual Surgical Planning | Mixed RealityChina
-
California State Polytechnic University, PomonaCompleted
-
BioLeaders CorporationCompletedCervical Intraepithelial NeoplasiaKorea, Republic of